Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|January 18, 2006
Factor VIIa inhibitors: gaining selectivity within the trypsin familyWilliam D Shrader, Aleksandr Kolesnikov, Jana Burgess-Henry, et al.
Bioorganic & Medicinal Chemistry Letters|May 3, 2006
Efforts toward oral bioavailability in factor VIIa inhibitorsDange Vijaykumar, Roopa Rai, Michael Shaghafi, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
3-heterocyclyl quinolone inhibitors of the HCV NS5B polymeraseDange V Kumar, Roopa Rai, Ken A Brameld, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2006
Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis modelWendy B Young, Joyce Mordenti, Steven Torkelson, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2022
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimizationBrahmam Pujala, Sreekanth A Ramachandran, Mukesh Sonawane, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2016
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomideRoopa Rai, Monali Banerjee, Darren H Wong, et al.
Bioorganic & Medicinal Chemistry Letters|October 9, 2016
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitorsPradeep S Jadhavar, Sreekanth A Ramachandran, Eduardo Riquelme, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical CharacterizationJ Brad Shotwell, Subramanian Baskaran, Pek Chong, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2017
Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitorsSreekanth A Ramachandran, Pradeep S Jadhavar, Sandeep K Miglani, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 17, 2017
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin's B Cell MalignanciesJennifer Alfaro, Felipe Pérez de Arce, Sebastián Belmar, et al.
Pageof 3